TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02116660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (MK-0518)
Description: Raltegravir (MK-0518) 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Nevirapine (NVP) 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine (3TC) 150 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir disoproxil fumarate (TDF) 300 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine
Description: Emtricitabine (FTC) 200 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir
Description: Lopinavir (LPV) 200 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Ritonavir (r) 100 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: Atazanavir (ATV) 300 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Darunavir (DAR) 400 mg tablets
Study: NCT02893774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life assessment
Description: All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis.~Those assessment will use standardized quality of life questionnaire :~* QLQ-C30~* SWLS (Satisfaction with Life Scale)~* PTGI (Post-Traumatic Growth Inventory)~* HADS (Hospital Anxiety and Depression Scale)~* Brief COPE~* MHLCS (Multidimensional Health Locus of Control Scale)
Study: NCT03446534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Imacillin mixture

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo manufactured to mimic amoxicillin mixture (Imacillin)
Study: NCT02763878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uncut Roux-en-Y anastomosis
Description: Uncut Closure devices would be used to close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Billroth II anastomosis
Description: Typical Billroth II anastomosis would be made after the Distal gastrectomy.
Study: NCT00422838

Intervention type: PROCEDURE
Intervention: fine-needle aspiration biopsy
Description: aspiration of intrahepatic cells

Intervention type: PROCEDURE
Intervention: fine-needle aspiration biopsy
Description: aspiration of intrahepatic cells
Study: NCT03399175

Intervention type: DRUG
Group type: OTHER
Intervention: Early high-dose corticosteroid and immunosuppressive therapy
Description: Early high-dose corticosteroid and immunosuppressive therapy
Study: NCT01517945

Intervention type: BEHAVIORAL
Intervention: AIM materials and assessments
Description: Phase 1 (complete) - dev of AIM materials targeting fear of cancer recurrence in BCS (n = 10).~Phase 2 (complete) - randomized, single-blind, placebo-controlled, proof-of-concept pilot trial.~Phase 3:~* Part 1 of Phase 3 (complete) - dev of of iThrive app for BCS~* Part 2 of Phase 3 (complete) - usability testing by observing navigation with BCS in a laboratory setting~* Part 3 of Phase 3 - acceptability of iThrive will be assessed through a small RCT (n=30)~Phase 4:~* Part 1 of Phase 4 (complete) - dev of iThrive app for RCS~* Part 2 of Phase 4 (complete) - usability testing completed by observing navigation with RCS remotely~* Part 3 of Phase 4 - acceptability of iThrive will be assessed through a small RCT (n=90)~For Phases 3 and 4, Part 3: We will work with participants to ensure that sessions are completed over \< 12 weeks if unavoidable delays occur. A follow-up session will be scheduled 3 months after completion of the last session.
Study: NCT02681952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renamezin capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renamezin capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kremezin granule
Study: NCT03341546

Intervention type: OTHER
Intervention: A single measurement of the patient's abdominal depth
Description: A single measurement of the patient's anterior-posterior abdominal depth
Study: NCT01001260

Intervention type: DRUG
Intervention: No ASA
Description: Alternative antiplatelet therapy instead of aspirin

Intervention type: DRUG
Intervention: Low dose ASA
Description: Low dose aspirin (81mg) prior to PTCA

Intervention type: DRUG
Intervention: 325 mg ASA
Description: high dose of aspirin prior to PTCA
Study: NCT01832727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib. Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib. Both formulations were administered in a single dose on dosing days. The tablet formulation required multiple tablets to reach each dose on dosing days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
Study: NCT02681952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kremezin granule
Study: NCT01832727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
Study: NCT04050631

Intervention type: BEHAVIORAL
Intervention: maternal arrest simulation on L&D floor
Description: AFE on L\&D
Study: NCT01215695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aScope (Ambu Inc. 6740 Baymeadow Drive Glen Burnie, MD)
Description: The aScope is a flexible, disposable plastic tracheoscope that incorporates a high-resolution video camera with an LED light at its flexible tip and has attached monitor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: pre-formed stylet provided by the manufacturer of the GlideScope® video laryngoscope
Study: NCT05112354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: systemic and intratympanic injection of steoid
Description: -If the patient come at first two weeks of onset of hearing loss the patient will be manged by oral corticosteroid in the form of ,prednisolone60mg in two divided doses for 2 weeks.~2-Patient will be manged by 5 sessions of intratympanic steroid after failure of systemic steroid and patient who come after 2 weeks of onset of hearing loss , each session will be 3 days apart. The injectable material will be 1ml of hydrocortisone 8ml. The injection will be done under local anesthesia and microscope magnification. A pack of lidocaine gel will be applied in the external canal for 10 minutes in EAC to induce anesthesia by using insulin syringe 1ml bore.~An 8 ml of hydrocortisone will be injected in the ME through posteroinferior part of TM All patients will receive antiviral therapy in the form of acyclovir,valcyclovir All the patient will receive vasodilator.
Study: NCT00597103

Intervention type: OTHER
Intervention: Cognitive Function Testing-10 Tests
Description: Trailmaking A, Trailmaking B, Rey Auditory Verbal Learning, Letter Number Sequencing, Digit Symbol Substitution, Grooved Pegboard, Controlled Oral Word Association, Beck Depression Index, Feeling Thermometer, Modified Mini-Mental Status

Intervention type: OTHER
Intervention: Cognitive Function Testing-10 Tests
Description: Trailmaking A, Trailmaking B, Rey Auditory Verbal Learning, Letter Number Sequencing, Digit Symbol Substitution, Grooved Pegboard, Controlled Oral Word Association, Beck Depression Index, Feeling Thermometer, Modified Mini-Mental Status
Study: NCT01832727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
Study: NCT01463150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 150mg per day for 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel 5mg per day for 15 days
Study: NCT00864617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine Extended Release tablets 60 mg, single dose
Description: A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under non-fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADALAT® CC Extended Release Tablets 60 mg
Description: B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under non-fasting conditions
Study: NCT01198834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-7EAT
Description: Application of up to two patches at the discretion of the investigator for up to 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of up to two patches at the discretion of the investigator for up to 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Application of up to two patches at the discretion of the investigator for up to 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac
Description: Application of up to two patches at the discretion of the investigator for up to 7 days.
Study: NCT02676284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durolane SJ
Description: DUROLANE® is a clear, transparent, viscous gel of highly purified, stabilized, non-animal-derived sodium hyaluronate that is biosynthesized using bacterial fermentation. NASHA technology is used to stabilize naturally entangled hyaluronic acid (HA) chains to produce a gel. The gel is suspended in phosphate-buffered saline at a concentration of 20 mg/mL .
Study: NCT00597103

Intervention type: OTHER
Intervention: Cognitive Function Testing-10 Tests
Description: Trailmaking A, Trailmaking B, Rey Auditory Verbal Learning, Letter Number Sequencing, Digit Symbol Substitution, Grooved Pegboard, Controlled Oral Word Association, Beck Depression Index, Feeling Thermometer, Modified Mini-Mental Status

Intervention type: OTHER
Intervention: Sleep Assessment Testing
Description: Sleep Assessment will be performed using an Actiwatch with subjects wearing the watch for 72 hours continuously

Intervention type: OTHER
Intervention: Sleep Assessment Testing
Description: Sleep Assessment will be performed using an Actiwatch with subjects wearing the watch for 72 hours continuously

Intervention type: OTHER
Intervention: Sleep Assessment Testing
Description: Sleep Assessment will be performed using an Actiwatch with subjects wearing the watch for 72 hours continuously
Study: NCT02088684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.
Study: NCT02315287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Comparison of two different thiazolidinediones

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lobeglitazone
Description: Comparison of two different thiazolidinediones
Study: NCT03854643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates group
Description: Pilates exercises were performed three times a week for 4 weeks, totaling 12 treatment sessions. Each session lasted 40 minutes and was performed by a researcher with training in the method and previous training in the exercise. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: These patients did not receive any type of intervention. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
Study: NCT02912000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEACH intervention
Description: The TEACH intervention screens family for three modifiable behaviors ahead of the clinical encounter: parental tobacco use, children consumption of sugar-sweetened beverages and child dental health. The information from the screening is then shared with clinicians.
Study: NCT00883480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/day 1 x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Cisplatin 75 mg/ day 1 x 4 cycles~Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg/day x 21 days
Study: NCT03419767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Patients under carotid revascularization surgery taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: blank
Description: Patients under carotid revascularization surgery without taking melatonin
Study: NCT04543474

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Lactose Diet
Description: First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Lactose Diet
Description: First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAP Diet
Description: First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAP Diet
Description: First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
Study: NCT03927508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-tPA
Description: Pulse spray and infusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bashir™ Endovascular Catheter
Description: The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
Study: NCT01887899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham stimulation
Study: NCT04136353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: 2 x 300mg oral tablets twice daily for 96 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 2 oral tablets twice daily for 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone-Releasing Hormone Analog
Description: All participants are to receive standard background therapy with an LHRHA, as per standard of care. The choice of LHRHA is at the discretion of the treating clinician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Luteinizing Hormone-Releasing Hormone Analog
Description: All participants are to receive standard background therapy with an LHRHA, as per standard of care. The choice of LHRHA is at the discretion of the treating clinician.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Description: All participants are to receive standard background therapy with curative-intent RT to the prostate or prostate bed as well as the pelvic lymph nodes using EBRT.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: External Beam Radiotherapy
Description: All participants are to receive standard background therapy with curative-intent RT to the prostate or prostate bed as well as the pelvic lymph nodes using EBRT.
Study: NCT03071536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft
Study: NCT04360616

Intervention type: DIAGNOSTIC_TEST
Intervention: imaging
Description: perform US and mammography examination

Intervention type: DIAGNOSTIC_TEST
Intervention: imaging
Description: perform US and mammography examination
Study: NCT05342129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise bike
Description: exercise is to use an exercise bike, start pedaling on the first day, time setting: 20 minutes, speed: 2, and adopt passive mode. If you can complete the exercise on the first day, the time will be adjusted to 30 minutes on the second day. If you cannot complete the exercise on the first day, the time will still start from 20 minutes on the second day. The maximum time is 30 minutes. If you can complete 30 minutes of passive exercise for 3 consecutive days, the fourth day will be adjusted to active exercise. The entire exercise training is seven days a week, once a day, once a 30-minute, at least 5 days. Those who were discharged to the general ward continued to complete this exercise training for up to 28 days.
Study: NCT00946946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: 2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: 4g Mesalazine tablets/day AND azathioprine placebo tablets
Study: NCT00597103

Intervention type: OTHER
Intervention: Periodic Leg Movement Syndrome Assessment
Description: Subjects will wear and Actiwatch on both legs for three consecutive nights.

Intervention type: OTHER
Intervention: Periodic Leg Movement Syndrome Assessment
Description: Subjects will wear and Actiwatch on both legs for three consecutive nights.
Study: NCT03455686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 129Xe MRI
Description: Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas is a research approach for the non-invasive visualization and measurement of lung structure and function.